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We present a case of Guillain–Barre´ syndrome (GBS) following Campylobacter jejuni HS
serotype O:19 infection in a child. Antibodies against C. jejuni and autoantibodies to the
peripheral nerve gangliosides GM1 were positive, a pattern correlating well with the
existence of an inflammatory neuropathy like GBS. The patient shared the HLA-B35 and
HLA-DR8 antigens, which have been found to be increased in GBS patients with previous
C. jejuni infection. As this is the first diagnosed C. jejuni-associated GBS case reported
from Greece, further clinical and epidemiologic investigations are warranted.
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Campylobacter jejuni is one of the most commonly
recognized causes of bacterial gastroenteritis. The
organism is transmitted via contaminated food
and water, and colonizes the intestinal tract of
many animals, including poultry, cattle and swine,
without causing any illness [1]. Campylobacter
enteritis is an acute diarrheal disease with clinical
manifestations like those of other acute bacterial
gut infections, and a definitive diagnosis can be
made only by detecting the organism in the feces
[2]. The disease is self-limiting, lasting for 3–
5 days. The rare extraintestinal infections include
bacteremia, hepatitis, cholecystitis, pancreatitis,
abortion and perinatal infection, hemolytic–ure-
mic syndrome, nephritis, proctitis, peritonitis,
myocarditis, and splenic rupture [3].
Postinfectious complications are triggered by
immunopathologic mechanisms and include reac-
tive arthritis, Reiter’s syndrome [4,5], and the
autoimmune-mediated disorders of the peripheral
nervous system, such as Guillain–Barre´ syndrome
(GBS) and Miller–Fisher syndrome [6,7]. The
last two may arise as the result of production of
antibodies to C. jejuni lipopolysaccharides, which
cross-react with gangliosides or other structures
present in peripheral nerves [8].
Several heat-stable (HS) O-serotypes (Penner
serotypes) of C. jejuni have been isolated from
GBS patients, and include O:1, O:2, O:4, O:5,
O:10, O:16, O:19, O:23, O:37, O:41, O:44, and
O:64 [9]. According to clinical and epidemiologic
reports from the USA, Japan, China and Mexico,
serotype O:19—a serotype causing mild gastroen-
teritis—seems to be over-represented in C. jejuni-
associated GBS patients [9]. Although the above-
mentioned GBS-associated serotypes are distribu-
ted worldwide [9], very few data are available
from Europe about the incidence of C. jejuni-asso-
ciated GBS and the serotypes involved.
We present a case of GBS following C. jejuni HS
serotype O:19 infection in a child. As far as we
know, this is the first case reported from Greece.
An 11-year-old-male was admitted to the First
Department of Pediatrics of Athens University,
‘Aghia Sophia’ Children’s Hospital, because of
muscle weakness of acute onset. The patient lives
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in a small town in central Greece. Family history,
pregnancy, delivery as well as motor and mental
development were normal. Ten days prior to
admission, the patient had a cough that lasted
for 3–4 days. Six days prior to admission, he com-
plained of intense abdominal pain that lasted for 1
day. He was examined in the local hospital, but no
firm diagnosis was established. Three days prior to
admission, he complained of muscle pains invol-
ving mainly the calf muscles. The pain increased in
intensity and, during the last day prior to admis-
sion, the patient was unable to walk.
On admission, his mental functions and his
cranial nerves were normal. He was unable to
walk and had a muscle weakness (grade 3 in the
0–5 scale) more prominent in the proximal muscles
of the lower limbs. A milder weakness (grade 4)
was found in the anterior tibial muscles and in the
distal muscles of his arms. Tendon reflexes could
be produced with great difficulty and were absent
in the Achilles tendon bilaterally. Sensory exam-
ination was normal. The rest of the clinical exam-
ination was also normal.
Laboratory investigations were as follows:
hemoglobin 13 g/dL, hematocrit 38%, white cell
count 9000 ml, polymorphs 63%, lymphocytes 30%,
and platelets 406 000/mL; creatin phosphokinase
(CPK), aldolase, serum glutamate oxalacetate
transaminase (SGOT), serum glutamate pyruv-
ate transaminase (SGPT), g-glutamyl transpepti-
dase (GT) alkaline phosphatase, urea, creatinine
and serum electrolytes were normal. Cerebrosp-
inal fluid (CSF) (on admission) yielded the follow-
ing findings: 4 leukocytes/mL, total protein
40 mg/dL, and glucose 55 mg/dL. A second CSF
sample (on the 10th day of hospitalization) show-
ed the following picture: 15 leukocytes/mL, total
protein 138 mg/dL, and glucose 65 mg/dL.
In view of the probable diagnosis of GBS, the
patient received from the first day of hospitaliza-
tion a course of intravenous immunoglobulin at a
dosage of 2 g/kg of body weight over a period of 2
days. The patient remained weak and unable to
walk for 5 days. During that period, cervical rigid-
ity was also noticed. After that period, a steady
improvement was seen. From the 11th day after his
admission, in view of the positive stool cultures for
C. jejuni (see below), he received oral erythromycin
1500 mg daily. On his 15th day of hospitalization,
he had only mild weakness (grade 4) of the prox-
imal muscles of the lower limbs, and minimal
weakness (grade 5–) of the muscles of his hands.
He was discharged on the 17th day after admission.
When re-examined 1 month later, he had no muscle
weakness and his tendon reflexes were brisk.
Special laboratory investigations for differential
diagnosis included antibodies to cytomegalovirus
(CMV), Mycoplasma pneumoniae, Epstein–Barr
virus (EBV) and rubella virus; results for all of
these were negative. Because of the clinical signs
and the history of a preceding gastrointestinal
infection, on the day of admission a stool specimen
was sent for bacteriologic and virologic (polio-
virus) examination to the hospital laboratory, as
well as to the National Reference Laboratory for
Campylobacter Serotyping of the Medical School of
Athens, in order to be processed with enrichment
culture isolation techniques for Campylobacter. The
sample was plated on Skirrow’s medium and
inoculated in Preston enrichment broth. Cultures
were incubated at 42 8C for 48 h in a micro-aero-
philic atmosphere (Biome´rieux, Marcy l’Etoile,
France), and then Preston broth was subcultured
on Skirrow’s medium and incubated for 48 h at
42 8C. Primary culture was negative for Campylo-
bacter, but the subculture of Preston broth yielded
a confluent growth of typical colonies for Campy-
lobacter which were oxidase and catalase positive.
The strain was identified as C. jejuni subsp. jejuni
through microscopic examination of fuchsin-
stained culture smears (S-shaped and curved
rods), positive hippurate hydrolysis, and differen-
tiation with the commercial system API-Campy
(Biome´rieux). Antimicrobial susceptibility was
tested by MIC determination with E test (AB
Biodisk, Solna, Sweden). The strain was suscepti-
ble to erythromycin, nalidixic acid, ciprofloxacin,
ampicillin, amoxicillin–clavulanic acid, and gen-
tamicin. Serotyping by the Penner method using a
commercial serotyping kit (Denka Seiken, Tokyo,
Japan) characterized the strain as serotype O:19.
Stool cultures requested on days 10 and 19 after
admission were negative for Campylobacter.
Three serum samples at about 7-day intervals
were requested for determination of antibodies
against C. jejuni and autoantibodies to the periph-
eral nerve gangliosides. Antibodies to C. jejuni
were determined by the indirect immunofluores-
cent assay using as antigen methanol-fixed whole
bacteria of the patient’s isolate (C. jejuni O:19). Five
pools, each consisting of 50 sera of healthy blood
donors, were used as controls. Autoantibodies to
peripheral nerve gangliosides, including monosia-
loganglioside (GM1), IgG and IgM, sulfatides,
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disialoganglioside (GD1a) and asialoganglioside
(ASGM1), were determined by the enzyme-linked
immunosorbent assay (ELISA), using methanol-
fixed antigen-coated 96-well microElisa plates and
peroxidase-conjugated secondary anti-IgG and
IgM goat antibodies [10].
On day 4 after admission, antibodies to C. jejuni
were positive in a serum dilution (titer) of 1 : 64,
while the control sera had titers of up to 1 : 8. On
days 10 and 19, the antibody titers were still
positive at 1 : 128. Anti-GM1-IgG antibodies were
positive in the first serum sample (day 4) in sig-
nificant titers (1 : 16 000, with negative controls
1 : 400) and shifted to negative (1 : 400) on days
10 and 19 after admission. All other anti-ganglio-
side antibodies were negative. The seropositivity
pattern to peripheral nerve gangliosides correlated
well with the existence of an inflammatory neuro-
pathy, particularly GBS.
The importance of host factors, such as HLA
antigens, in the pathogenesis of C. jejuni-associated
GBS has been pointed out. In some research stu-
dies, however, subgrouping of GBS patients
according to C. jejuni infection revealed a tendency
for an increased frequency of HLA-DRB10803
[11], or an increased frequency of HLA-B54 and
–CW1 [12], HLA-DQB103 [13] and HLA-B35 [14].
Thus, HLA haplotypes of our patient were deter-
mined in order to reveal any matches with the
worldwide data.
HLA class I and II phenotypes and genotypes
were established by serologic and molecular tech-
niques, respectively. HLA class I (A, B, C) and II
(DR, DQ) specificities were determined by serolo-
gic (NIH standard technique) and molecular tech-
niques at the genomic level, for all the specificities
included in the HLA Nomenclature of 1998 [15]
(Elpha-Biotest, High Resolution, Germany; Pel.
Freeze, Medium Resolution, USA; Inno-Lipa,
Murex, Belgium).
Our patient shared the HLA-B35 and HLA-DR8
antigens that have been found in increased pre-
valence in GBS patients with previous C. jejuni
infection, both in Japanese groups of patients
[11,14].
The neurologic signs of a peripheral neuropa-
thy, the history of a preceding gastrointestinal
infection, the isolation of C. jejuni serotype O:19
from the patient’s stool, the positive anti-GM1-IgG
antibodies and typical immunogenetic profile are
typical of a C. jejuni-associated GBS. So far, there
have been no reports about the incidence of such
cases in Greece. As far as we know, C. jejuni Penner
serotype O:19 is one of the most commonly
encountered in GBS in the USA and Japan [9].
In a C. jejuni serotyping study of strains from
infected children in Athens, serotype O:19
accounted for 1.6% of all serotypes (unpublished
observations), a rate commensurate with those
reported from the USA and Japan [9]. However,
in a British study, none of four C. jejuni isolates
from GBS cases were O:19 [16].
The clinical entity ‘GBS’ can be divided into
three forms: the acute inflammatory demyelinat-
ing polyneuropathy (AIDP), which has as its main
characteristic feature the macrophage-mediated
demyelination of the peripheral nerves; the axonal
pattern—with axonal involvement—consisting of
the acute motor axonal neuropathy (AMAN), and
the rare acute motor-sensory axonal neuropathy
(AMSAN); and Miller–Fisher syndrome, charac-
terized by acute onset of ataxia (unsteadiness of
gait, areflexia (loss of reflexes) and ophthalmople-
gia (an inability to move the eyes) [17]. The differ-
entiation between AIDP and AMAN is based
on the different clinical, electrophysiologic and
serologic manifestations. In the present case, the
electrophysiologic manifestations could not be
evaluated, as an electromyogram (EMG) had not
been requested because of the mild clinical course
of the disease and the quick recovery. This mild
clinical course, in association with the presence of
anti-GM1-IgG antibodies only, is more compatible
with the less severe form of AIDP [9]. GBS follow-
ing C. jejuni infection may be more severe than
GBS following other inciting events [18]. However,
the quick recovery of the patient in the present case
may be due to the early onset of treatment with
intravenous immunoglobulin.
Concerning the bacteriologic diagnosis, the role
of enrichment broth (Preston broth) was remark-
able in the isolation of Campylobacter from the
stools of the patient. The use of enrichment culture
in the investigation of patients with acute Campy-
lobacter diarrhea has been contested, but it may be
beneficial in instances where small numbers of
organisms may be expected [19]. There is a lag
time of 1–3 weeks between campylobacter infec-
tion and the onset of GBS. Since the median period
of excretion of Campylobacter from stool samples is
only 16 days [20], at the onset of GBS bacteria are
either absent from stool, or present in very low
numbers, and enrichment cultures enhance the
possibility of detecting them.
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The over-representation of certain HLA alleles
in GBS patients, especially in those with previous
C. jejuni infection, has been estimated in popula-
tion studies, in different ethnic groups. For the
Greek population, there are no data currently
available, but our ongoing association study seems
to reveal a tendency for an increased frequency of
HLA-B35, HLA-B44, HLA-DR11 and HLA-DR13
[21] in the GBS group as a whole. Thus, no inclu-
sive results or comments can be elicited, before an
association HLA study is completed, but the
fact that our patient has, at the same time, two
of the five HLA antigens that have been associated
with C. jejuni-positive GBS patients, even with
different immunogenetic backgrounds, supports
the ‘immunogenic’ character of these antigens in
the pathogenesis of GBS.
In many countries, special care is given to the
elimination of Campylobacter from its natural reser-
voirs, especially poultry, in order to decrease the
incidence of enteritis, as well as the incidence of
the sequelae of infection. GBS is the most severe of
them, in terms of clinical outcome and costs of
treatment. As this is the first case reported from
Greece, further clinical and epidemiologic inves-
tigations are warranted.
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